Originally spun out from the US Army Research Laboratory and having now more than two decades of experience, ANP Technologies, Inc. is a nanobiotechnology company focused primarily on design, development, and marketing of innovative technologies: cutting-edge technology platforms addressing: Specialty CRO for biological drug R&D; Biodefense and homeland security; Home/point-of-care diagnostic systems and Nanoencapsulation and targeted drug delivery and therapy. ANP has been a provider of rapid, multiplexed lateral flow tests for the detection of various biological agents for DOD several years and has successfully licensing various pre-clinical and clinical stage nanotherapeutics to companies such as Celgene/BMS and Fulgent Pharma. Additionally, more recently ANP has developed COVID-19 antigen and neutralizing antibody rapid tests
